Clinical Trial Update: Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in adults on chronic hemodialysis with recur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hyperkalemia

Drugs mentioned

• Lokelma (sodium zirconium cyclosilicate)

Snippet

Sponsor: AstraZeneca | Conditions: Hyperkalemia | Phase 3 | Status: TERMINATED | Results posted: 2025-06-18